Bionomics IPO Presentation Deck

BNC210 Potentially Addresses the Shortcomings of Existing Social Anxiety Disorder Approaches 13 Novel Mechanism of Action Potential Large Market Potential for Social Anxiety Disorder Bionomics BNC210 Potential for Acute Treatment in Social Anxiety Disorder Patients Anti-Anxiety Effects In healthy subjects (anti-panic) and GAD patients (anti-anxiety) Attractive Clinical & Regulatory Pathway Rapid Onset of Action CURRENT THERAPIES FOR THE TREATMENT OF ANXIETY AND STRESSOR-RELATED DISORDERS* DRUG FAST ACTING Benzodiazepines ✔ NO NO NO WITHDRAWAL NO MEMORY MOTOR SEDATION SYNDROME IMPAIRMENT IMPAIRMENT X X X X SSRIs/SNRIS X ✔ X ✔ ✔ BNC210 IS DESIGNED TO PROVIDE POTENTIAL ADVANTAGES COMPARED TO CURRENT THERAPIES* *Potential benefits based on analysis of data prom separate studies are not on results that have been obtained from head-to-head studies Such das may not be directly comparable due to offerences in shady protocols condicions and patient populations Accordingly cross-treal compansans may not be able predictors of the relative activity or other benefits of BNC2 10 compared to existing theraps or other product candidates that may be approved or are in development for the treatment of PTSD or SAC The potential benefits of BMC210 does not imply an expectman of regulatory approval which is solely within the authority of the FDA for applicable for regasto T includes Values and certae other benzodiazepines includes Prator and certain other SSR elective Senatonin Reuptake inhibitor/ Beraton-orepinephine napake inhibitor

View entire presentation